A New Approach to Improve Effectiveness of Cancer Therapies

Dear Friends,

Today is October 18th 2018. That is exactly two years since my dear wife became an angel and exactly one year since the incorporation of MCS Foundation for Life with the aim of helping advanced cancer patients to live a better and longer life.

I promised I am going to share with you some very exciting news regarding a new treatment approach that based on early and anecdotal reports, in my view, represents one of the most promising approaches to treat cancer.

I will use this special day to release these news:

The project

Lampidis Cancer FoundationUSA (website), together with MCS Foundation for Life (website), are actively preparing to collaborate with clinics worldwide on implementing protocols using 2-DG for patients who have failed standard treatment. This is a massive step towards making 2-DG accessible to cancer patients worldwide.

The details of this project have been made available at the website of Lampidis Cancer Foundation here.

Essentially, this new project relates to a new method to deliver 2DG to cancer patients, in a metronomic manner, meant to improve or enable effectiveness of conventional therapies including but not limited to chemo- and radio-therapies.

2DG has been previously discussed on this website (Ref.) and has been already given to cancer patients both in the context of clinical trials performed years ago in USA, and in private clinics around the world including in German clinics. But the results were not as exciting as expected.

Today, based on the research findings of Prof. Lampidis, professor of cell biology at the Miller School of Medicine in Miami, we now understand that when 2DG was given to the patients in the past trials, because 2DG “looks” like glucose, there is a subsequent release of insulin in the human body, redirecting 2-DG to fat and muscle and away from the tumor site. As a result, when given all at once, 2-DG cannot reach the tumor tissue at the relevant amount and for a long enough time-frame required to have a negative impact on cancer cells, similar to that observed in laboratory. That is not what we want.

A new approach to get 2-DG into the tumors

In order to avoid the insulin release and get the 2DG to the tumor, Prof. Lampidis came up with a trick. Instead of giving the 2DG all at once as it is being given typically to patients around the world, Dr. Lampidis proposed to give that in a much lower dose and during long time, up to a few days, at a rate and concentration that is below the insulin-inducing dose. That is what we call metronomic delivery of 2-DG.

It is not a question but a certainty that 2DG will reach the tumor at a very low dose. Why? Because 2DG is the very same substance that is used in the solution given to the patients prior to PET-CT scan. In that scan, 2DG is connected to a radioactive substance. Because 2DG looks like glucose, and because we know very well by now that tumors like glucose, 2DG will be absorbed by the tumors while the radioactive substance will behave like the blinking light sending the signal outside the human body and indicating the location of 2DG. That is how PET-CT works. And so from PET-CT scans we know that the absorption of 2DG at low dose is very selective and mainly absorbed by the tumors.

Using the strength of 2-DG to help conventional therapies work

Once getting the 2DG to the tumor, this will put pressure on the tumor via various mechanisms, including the reduction of energy (ATP) production which is required by the multi drug resistance (MDR) pumps to push chemotherapy out of cancer cells and including the reduction of anti-oxidant production required by cancer cells to fight the pro-oxidant nature of chemo- and radio-therapy. Prof. Lampidis has identified other mechanisms that may be even more relevant than these two and will be further discussed as soon as I get further clarity on that line.

Now imagine that we can use such an approach to put pressure on cancer cells, and lower their capability to fight conventional therapies. Imagine that we can use this while or just after the conventional therapies are given to the patient. Imagine how more effective the conventional therapy may become. And that would be nearly independent on the cancer type since most of the tumors are relying on glucose for the short term need of resources. Actually, we do not even need to imagine how much the conventional therapy can be improved. Instead, read this post I wrote some years ago, when a substance working in a “similar” fashion could be used in a hospital in US to make advanced cancer patients respond again to conventional therapies. Actually, the dose of conventional therapies could even be reduced when supported by a substance “similar” to 2-DG.

Next to the very clear and extensive scientific evidence supporting 2-DG, the prior results mentioned at this post is what made me very enthusiast when I head about the findings of Prof. Lampidis on metronomic 2-DG. The great advantage of 2-DG is that is a substance already used in humans, in clinical trials and in PET-CT. It’s safety profile is relatively well known and with limited or no toxicity. It is accessible as it is produced at compounding Pharmacy in Germany ready for intravenous administration. And it’s cheap. Perfect combination of attributes: effective, safe at known doses, accessible & cheap.


The implementation of this new approach to help enable and/or increase effectiveness of conventional therapies, is beeing done in 3 different steps:

  1. Implementation on a compassionate basis, by clinicians located in countries and institutions where this is allowed
    • Here, Lampidis Cancer Foundation & MCS Foundation for Life, informs the patients and clinicians, and supports clinicians with knowledge during the implementation
  2. Implementation via limited number of clinics around the world that can receive the approval to do so in a structural manner (such as being done by DaySpringClinic in USA with other substances)
    • Here, Lampidis Cancer Foundation & MCS Foundation for Life, supports a few selected clinics with the documentation required for application for approval at the relevant boards
  3. Implementation of 2-DG as a widely available drug, which will require FDA approval and clinical trials before that

At this point, there is a treatment protocol in place that is shared by Lampidis Cancer Foundation & MCS Foundation for Life on compassionate basis with clinicians around the world, addressing point #1 above. At the same time, the two foundations and collaborators, are working on point #2 and #3 above.

Patients interested in learning more about this approach can contact us and will be glad to inform.

Medical doctors interested in learning more and implementing this approach can contact us and will be glad to inform and continue supporting with our knowledge during the implementation process.

Please note that this is an intravenous (IV) treatment.

Very encouraging anecdotal reports

Although the data is still at an anecdotal stage, it is encouraging to know that multiple patients across the world are reporting excellent tolerance with metronomic 2-DG treatment, when used immediately after chemotherapy.

While these patients are being co-treated with other agents as well, they all seem to experience positive outcome following the treatment approach that includes metronomic 2-DG, from just feeling better to reduction in the size of their respective tumor types and markers.

All of the patients are advanced cancer patients with no or limited treatment options. While we do not have the consensus to publish their data yet, I can at least shortly and anecdotally mention several cases:

  • Endometrial cancer
  • Colon cancer
    • 70+ women; colon cancer & liver metastasis; 18% marker reduction after one week treatment
  • Brain cancer
  • Pancreatic cancer
    • 70+ man; pancreatic cancer with liver metastasis; tumor markers exploding during the summer; Gemcitabine only stopped the growth of markers; implemented metronomic 2DG and several other treatments. 90% decline of tumor markers in the following two months (family of patient will create own website to share experience – I will share the link as soon as that is available)
  • Sarcoma
    • 30 yeas old lady; sarcoma with metastasis; combining IPT (low dose chemo) with 2DG metronomic and a few other treatments and reporting feeling better, and feeling regression of some palpable tumors
  • Ovarian cancer
    • 50+ women; ovarian tumor with mets at liver, spline, ascites fast evolving; started two months of IPT (low dose chemo) & metronomic 2-DG and a few other treatments; two months after no tumor visible on MRI and patient feeling well

So far, the results we hear back are along the line of our expectation, and I am veryy happy to be able to say that. It’s important to say that the reports from nearly 100% of the patinets I know using it are indicating improvements.

The international team behind the metronomic 2-DG project

Dr. Metin Kurtoglu holds an MD and Ph.D. in cell biology and is one of the world’s leading experts in the mechanisms by which 2-DG works as well as its clinical application. Dr. Metin Kurtoglu and Dr. Theodore J. Lampidis have worked closely together and have published extensively on 2-DG as an anti-cancer agent. Dr. Kurtoglu, based in Washington DC, is also developing a novel CAR T immunotherapy that is currently in Phase I clinical trials.

Dr. Daniel Stanciu, holds a Ph.D. in physics and has become knowledgeable in traditional as well as new cancer treatments since his beloved wife Mihaela, who recently passed away, was diagnosed with cancer in 2013. Daniel is now devoting his life to helping others suffering from this devastating disease, through the MCS Foundation for Life. He has attracted a following of more than one million views to his blog, where he presents scientific information consolidated around new or improved approaches to treat advanced cancer.

Dr. Theodore J. Lampidis, Ph.D. is a professor of cell biology at the Miller School of Medicine in Miami, trained at the Dana Farber Cancer Institute, Harvard Medical School, and whose lab is internationally known for its work on developing 2-DG as a universal treatment for numerous cancer types. Dr. Lampidis is a leading authority on exploiting cancer glucose metabolism with sugar analogs.

The role of the two Foundations:

Lampidis Cancer FoundationUSA (website), based on the extensive knowledge acquired from prior research and prior clinical trials on 2DG, is in the lead for the following:

  • establishing and sharing the metronomic treatment protocol with medical doctors interested
  • supports clinicians during the implementation process, when required
  • translates report results into potential next steps including documentation required for the required steps in clinical trials
  • publication of results in scientific papers, and communication with the academic and medical communities to enable next steps

Therefore, main focus and experience of Lampidis Cancer Foundation is around the implementation of metronomic 2DG.

MCS Foundation for Life, (website), based on the extensive knowledge acquired from prior research and application on cancer treatments, as well as constant contact with patients and clinicians across the world, is in the lead for the following:

  • contributes to the establishment and adaptation of the metronomic treatment protocol
  • informs and maintains contact with patient and medical communities
  • supports patients and their doctors with the integration of the metronomic protocol as part of larger treatment strategies
  • collects and consolidates reports on results, to inform communities and to be further translated into documentation

Therefore, main focus and experience of MCS Foundation for Life is around the integration of metronomic 2DG.

Another activity that is currently the focus of both of the foundations is finding ways to fund the next steps of this project, with the goal of helping as many patients as possible across the world.

All activities described here are going with the disclaimers presented on this website and at Lampidis Cancer Foundation http://lampidisfoundation.org/2-dg-cancer-treatment-begins-human-trials/


The results of this work that we saw so far and will further experience, are not only due to the team and foundations mentioned above but also and more importantly due to the professional attitude of many people involved including medical doctors, patients and their families.

I would also like to thank you (the reader) in advance for sharing this post on social media platforms such as Facebook & Twiter, to create awareness. You may save a life with that.


Donations to support the progress and acceleration of this project can be done on this website via the Donation option located at the right side of the page (when doing the donation please add a note “support 2DG project”).

Important Notices & Disclaimers:

All rights reserved. The material may not be reproduced or distributed, in whole or in part, without the prior written permission of the Cancer Treatments Research. For further information, please contact Cancer Treatment Research.

This site is not designed to and does not provide medical advice, professional diagnosis, opinion, treatment or services to you or to any other individual. Through this site and linkages to other sites, I provide general information for educational purposes only. The information provided in this site, or through linkages to other sites, is not a substitute for medical or professional care, and you should not use the information in place of a visit, call consultation or the advice of your physician or other healthcare provider. I am not liable or responsible for any advice, course of treatment, diagnosis or any other information, services or product you obtain through this site. This is just my own personal opinion regarding what we have learned on this road.

Please read an extended version of the Disclaimer here: https://www.cancertreatmentsresearch.com/?page_id=1794

Related Articles

141 thoughts on “A New Approach to Improve Effectiveness of Cancer Therapies

  1. Wow!
    Daniel this is very exciting!
    This is something that could roll-out in the near term to help cancer patients!

    To clarify, is the idea to give continuous low doses of 2-DG for days at a time?
    I found this duration dosing energy depleting treatment strategy using vitamin C to be a highly compelling.
    If this is what metronomic dosing is, then I would think that it could be highly effective.

    2-DG takes an ATP through phosphorylation by HK and then gives back 0 ATP.
    A treatment that generates negative ATP has to have serious anti-cancer potential.
    By continuing this treatment through time, cancer cells should become energy depleted.
    Of course with the enormous appetite for glucose that cancer cells have, there would be selectivity of 2-DG effect.
    2-DG is perhaps even better than 3-BP as an energy depletor because it is hard to imagine any cancer that would not have abundant glucose transporters. With 3-BP, some cancer cells are lacking in MCT-1 transporters.

    D, has any consideration been given to formulation of the 2-DG for the trial?
    Using chitosan 2-DG might be an idea. Delivering at least some of the 2-DG with this formulation would deliver the 2-DG directly to the cancer cells.

    The Miami website does note that some QT side effects would need to be monitored.
    Perhaps the metronomic dosing could be cycled with other ATP depletors (such as Vitamin C and others) to reduce such potential
    side effects.

    The fact that 2-DG is a widely used drug, it should allow for a much more rapid roll-out then would occur with a new drug entity.
    One might anticipate that with such obvious upfront value to patients, raising money to collectively develop this idea should not now be overly difficult.

    D, might you know which nations have approved 2-DG for clinical treatment? The clinical trials to date had not been seen as overly successful, so I was surprised that patients are being treated with it. Yet, given this new treatment rationale, several of those on our forum might be interested in this treatment approach. I will be very interested in seeing what co-treatments might be added in to enhance effectiveness.

    Great job D!

    1. Hi J,

      Yes, this is something that is so easy to roll-out and implement, given it’s accessibility, cost and safety profile!

      1. Yes, J, the idea of metronomic 2DG is to be given for days at a time – the details of the procedure can be made available (at no cost) to any medical doctor that is interested. If patients are interested, they just have to ask their medical doctor to contact us.

      2. Phlorizin (referenced above) was also given in a metronomic fashion next to chemo and the presented results were great. I now see we start to get the same on the metronomic 2DG route. Just that it is easier to implement.

      3. Other re-purposed drugs can be used to increase the effectiveness of the approach. For example combination with Metformin, that would both inhibit mitochondria (and up-regulate glycolisis) but also reduce the blood glucose levels so that 2DG will be absorbed even better by the tumors.

      4. The metronomic Vit C is something that is my mind as a interesting method to further investigate. But I had no chance to spend enough time think about that, yet. But now, stepping into metronomic space, asap I will look in to it.

      5. You brought into the discussion 3BP which is a very good point – that reminds me that in another post we should discuss potential combinations of bolus 2DG & metronomic 2DG with others.

      6. Regarding new formulations, and looking at a PET-CT, the selectivity of 2DG to tumors is high enough that we do not need at this point to look into new formulations. Actually, given that selectivity, you could think of using 2DG as a targeting substance and combine with other substances toxic to cancer cells.

      7. Very good point J: actually the ovarian cancer patinet mentioned above intercalated vit C between the cycles of IPT+chemo+2DG

      8. Would be great if we could find ways to raise money fast to advance this approach. Even large pharma companies should be interested since it helps their drugs be more effective. And we also know they are intensively looking for such solutions, as the society puts pressure on the industry to come up with more effective solutions to cancer.

      9. We are now looking at what countries have regulations in place to allow the use of substances such as 2DG. The great thing is that 2DG is well-known and has been used in humans, and has strong science behind, which is required for use on compassionate basis. Many countries allow doctors to apply such new treatments when the patient has no other options. One such example is Germany and there is a reason why the German pharmacies have 2DG solutions ready-made for intravenous administrations. But yes, we are looking into identifying countries where adoption and implementation is easier. That in part of implementation action #1 above. But in parallel to that we are working on the other two routes mentioned above. Of course, if anyone has ideas for other routes to implement ion, we are happy to consider those ideas.

      10. Yes, J, cotreatment approach is KEY towards maximizing the value of this approach. This is actually a global trend in the clinical trials. An example is what Marcos is doing in terms of cotreatment https://www.cancertreatmentsresearch.com/community/forum-to-discuss-treatment-protocols-and-drugsupplement-cocktail/treatment-protocol-from-endometrial-carcinoma-stage-4/
      Cholesterol depletion could help 2DG be more effective. I had so info on that but cannot find it now. I will anyway search for it because this may be a key aspect.

      Thanks again J!

      Kind regards,

    1. Dear Alex, thanks for your question. Thinking along your suggestion, a good idea could be to do IPT with chemo (even if chemo is low-dose) and 2-DG (bolus) followed by metronomic 2DG. This is a relatively similar approach used for the stage IV ovarian cancer patient who obtained complete remission after about two months involving several cycles of these combinations. The drawback of IPT+2DG alone would be that the exposure of the tumor to 2DG would be for too short time frame, while a lot of 2DG will be absorbed by the body due to the injected insulin, which is what the metronomic approach want’s to avoid.

      1. Thank you, Daniel for your answer.
        The point is that when you do IPT, you have a time interval (abot 5 minutes), just before the patient gets hypoglicemic, when the cancer cells are permeable and the normal ones not yet. The drugs (whatever they are – chemo, botanics etc) should be delivered in this interval and a big part of them go in the cancer cells. Thus, the quantity of drugs used is smaller then in normal therapy and in the same time the uptaken quantity in the cancer cells is higher. This is why it is effective with chemo and with much, much less side effects.
        So, I was thinking about the possiblilty of using also 2-DG this way – in smaller doses than the regular ones used, so that you just don’t get the normal cells affected. The metronomic administration via an elastomeric pump may be quite a burden for some patients, not because of some pain or physical discomphort, but rather phsychic.
        Meantime, after I wrote the first comment, I discussed with a doctor, firnd of mine, wh tried this, but he said he wouldn’t try again because of the side effects of bolus administering of 2-DG. Still, I didn’t discuss about the dosage and maybe this is the key.

        1. Thanks Alex. I understand the claims behind IPT and have a good feeling about it, specifically as a way to use lower dose chemo. The mechanism related to the permeability of the cell membrane it is still questionable from my point of view. I nee to dive deep into the literature to see how valid is this claim. The second mechanism behind IPT (that makes very much sense, but only for Chemo and not other substances), is related to the fast glucose absorption triggered by injected insulin. That in turn accelerates glycolisis and makes the cancer cell more susceptible to chemo as chemo will affect stronger the more active cancer cells. In that was a lower chemo dose could still work. This second mechanism is clear. But it’s only relevant to chemo and it may explain why IPT is used mainly with chemo.

          Using IPT+2DG sounds interesting but would be purely experimentally as there is not much knowledge on that line. I would indeed expect that injected insulin will trigger fast absorption of 2DG, but that would not be so much different compared to teh results from clinical trials, I think. This is because the issue is exactly that: insulin release following 2DG bolus will trigger its absorption “everywhere” in the body. The permeability possibly induced by IPT is not needed for 2DG because the cells already have many glucose transporters ready to receive that.

          Beyond that, I would say that “Changing the winning team” makes sense only to try improving the current “metronomic 2DG” at the point when this approach doesn’t show results to a specific patient. Otherwise, I would stay with the treatment approach used so far as it appears to show good results.

          I do not know what could be the side effects of the approach you mentioned (IPT+2DG) but what I know is that 2DG bolus at a dose of e.g. 500mg in one hour given as IV does not show any special side effects (typically). However, I can imagine that could lead to side effects if the medical doctor accelerates the absorption of that with prior admin of insulin.

    1. Its difficult to make a statement o that, since the patient would not be able to take it continuously and since before getting in to the blood there may be different dynamics in different patients when taken via oral route. But it could be better than nothing to support conventional therapies.

  2. D, the Lampidis Foundation website mentioned research with lab models that established the effectiveness of the metronomic metabolic depletion approach. Might you know of any references for this? I would love to see the comparison between metronomic and standard treatment for 2-DG, 3-BP , vitamin C etc.

    Here are some of the exciting articles that I have read recently:

    PMID: 24158437 In pancreatic cells which are glycolytic, 3-BP treatment lead to permanent Calcium overload.
    Apparently, the ATP supply for the PMCA (calcium pumps) is sequestered either with the
    glcolysis path or the OXPHOS path. This might partially explain why cancer cells are so
    glycolytic: They need the glycolytic ATP to pump out the calcium! Actually, cells appear to
    use a fair amount of their ATP to pump out calcium, Na, K etc. Overloading the cell with calcium
    and at the same time depleting ATP might be a good combo.

    PMID: 26294767 In this follow up article they looked what would happen when the glycolytic cancer cells were transformed into
    oxidative cancer cells. What was fairly surprising was that they were able to do this by simply “supplementing
    with α-ketoisocaproate or galactose”. Notably, transforming the cancer cells in this way reduced their
    “proliferative rate” (see below). This has been something that I have been unsure about for quite some time.
    If you simply move cancer cells into an OXPHOs state from glycolysis, then how is this helpful? As the article
    finds, OXPHOS is a less virulent cancer state and as you have noted, there is then the opportunity to shut off
    the cancer cells OXPHOS energy. Notably, 3-BP can shut off glycolysis and OXPHOS selectively through MCT-1.

    “The highly glycolytic phenotype of these cells was first reversed by depriving MIA PaCa-2 and PANC-1 cells of
    glucose and supplementing with α-ketoisocaproate or galactose. These culture conditions resulted in a
    significant decrease in both glycolytic flux and proliferation rate, and conferred resistance to ATP depletion by
    glycolytic inhibition while sensitizing cells to mitochondrial inhibition. ”

    PMID: 24166504 This was another exciting one! Glucose deprivation can upregulated MCT-1.

    “While this posttranslational induction could be recapitulated using glycolysis inhibition, hypoxia, oxidative
    phosphorylation (OXPHOS) inhibitor rotenone or hydrogen peroxide” Hydrogen Peroxide! This had me thinking
    about vitamin C treatment. If you could upregulate MCT-1 with vitamin C due to the hydrogen peroxide,
    glycolysis inhibition, and ROS generation (see note 1 below), then you could cycle back with 3-BP once the
    MCT-1 is activated.

    “That ROS can stimulate MCT1 and CD147 protein expression was established by showing a B 2-fold increase in
    the expression of both proteins 24 h after treatment with 0.8 m M H 2O2” PMID: 24166504 (Open Access)

    PMID: 26708213 Sodium Citrate! Look at Figure 5A. High dose Sodium Citrate massively reduces ATP. For some reason tehy do
    not show the ATP out at 24 and 48 hours, though in Figure 5B the lactate levels at 48 hours of the cells treated
    with sodium citrate are extremely reduced. Has metronomic sodium citrate been shown safe in humans? Is
    anyone aware of research that looks at metronomic metabolic depletion?

    Look at Figure 4A, high dose 3-BP massively reduces HK activity! Especially look at 48 hours; it’s almost 0! At
    those levels of ATP production cancer cells would simply no longer be viable. Cancer cells need a minimum of
    10-20% of normal ATP production to maintain viability. Look at Figure 4B, sodium citrate almost stops PFK-1
    activity at 48 hours. One would certainly wonder what would happen with a 3-BP and sodium citrate combo.

    Figure 1D. I have been wondering about cancer cell cycles with respect to metabolic applications for quite a
    while now. If you could synchronize cancer cells into a high ATP part of the cell cycle ( S phase?) and then treat
    with an ATP depleting treatment, then this could be even more effective. Figure 1D shows how the different
    treatments can manipulate cells into different parts of the cell cycle. Cancer cells move through the cell cycle
    more rapidly than other cells, so this should selectively stress the cancer cells with a metronomic dosing
    approach. Great part with metronomic dosing is that with prolonged dosing you will automatically be able to
    benefit from this effect. Yet, with traditional short term dosing schedules this would not automatically occur.

    Figure 1B shows how 100% cell inhibition rates occur with 3-BP and sodium citrate after only 2 days of in vitro
    dosing. Would be great to see this in vivo.

    D, metronomic metabolic treatment is superexciting! The focus of research until now has been almost entirely focused on the idea of giving people the maximum possible dose. Using a maximum dose strategy meant that patients would need time to recover after
    intense treatment with often substantial side effects. In the context of cancer, maximum dosing is an extremely misguided approach. All that you are doing is selecting the most malignant cells. Sure you can obstensibly have large responses, though now when relapse occurs the treatment will no longer be effective. Metronomic metabolics would to a large extent avoid this. If the treatment can be tolerated essentially indefinitely, then there is no longer a time for a super resistant cancer line to emerge. In fact, what happens is that you are pushing the cancer cells to evolve towards OXPHOS which is a less aggressive cancer phenotype. Of course knowing that the cancer cells have been moved in the OXPHOS direction then gives you the opportunity to treat with OXPHOS inhibitors.

    I am not aware of this approach ever being tried before. The research to date almost always stops after 5-48 hours. Depleting ATP or even just stressing metabolic pathways in other ways ( though ATP depletion would be the most direct) for days at a time should lead to very extreme responses. I found this approach which I referred to as duration dosing on the Vitamin C thread to be highly compelling (https://www.cancertreatmentsresearch.com/high-dose-vitamin-c-cancer/ see my post on April 13, 2017).

    If we can all move toward a common protocol, then we could leverage the group knowledge and perhaps find an effective and safe cancer treatment. There might be dangers using various variants of the metronomic approach, though many of these treatments have been used safely already in many patients for many years using the maximum tolerated dosing appraoch.

    1. Hi J,

      Answering shortly to each point due to time constrains:
      – I will need to look back for the reference, if I forger please remind me
      – ATP is indeed essential for many processes required to support fast division -> no ATP, no fast division
      – The above applies indeed to the switch from fermentation to respiration inside the cell, as mentioned in the ref you sent – but we still need to address those cells that a developing slower based on respiration – that is why, for me 2DG like substances are essential but they need to be part of a larger approach that would also attack the pure oxidative cells (such as chemo, etc.)
      – Indeed it makes sense that MCT1s will be upregulated when too low glucose is available as the cell will try to switch on alternative supplies to generate ATP in the mito. Actually some of the patients using 2DG metronomic have also used the substance you are thinking of now 🙂
      – Regarding your question: “”Has metronomic sodium citrate been shown safe in humans? Is anyone aware of research that looks at metronomic metabolic depletion?” The first one I do not know. The second I need to check, but the best answer is to look at the patients that used Phlorizin, and the success in that.
      – You stated “D, metronomic metabolic treatment is superexciting!” – I so much agree with this. This is why I liked the Vitamin C idea as well, just that Vit C can only have the fermentation inhibition activity in high dose. Using Vit C in high dose for long time is not sustainable. And in addition, we do not know if Vit C will always get to the tumor.
      In contrast to that, what PET CT scan tells us is that 2DG virtually always get’s to the tumor. It’s as simple as that. The fact that PET-Ct works and is used world wide for all cancer patients, tells us about the relevance of 2DG and how easy is to get that to the tumor even in very low doses. 🙂
      – most of the people I know who used 2DG metro, have also used OXPHOS inhibitors according to many of ours discussions and understandings, including about the right timing of those when integrated around chemo.
      Kind regards,

        1. Hi J, you better contact Prof. Lampidis at Lampidis Foundation (link above) and ask him if he could share something with you on that line as I am not sure if he published the findings yet. It would help me if you do that, so I can focus on other points. Thanks.

          1. D, this is a reference for metro 2-DG with fenofibrate in vivo.
            Look at Figure 2! So fenofibrate + 2-DG greatly reduces ATP and also greatly increases lactate? Are you thinking what I am thinking? Might not a dose of 3-BP be then in order? The high lactate production would further acidify the tumor environment leading to 3-BP entry, it would also likely upregulate the MCT-1 transporter; the cells are alrady approaching an energy crisis, 3-BP would simply push down energy even more.


  3. Hi Daniel,

    I am thinking adding a statin to decrease cholesterol uptake and improve 2 DG……

    I think that an alternative to less aggressive sodium phenylbutyrate to inhibit glutamine may be to add iodine L2 and green tea to partially inhibit GDH glutamate enzymes.

    What do you think about?

    1. Hi Manuel,
      I do find statin drugs as good tools to address intracellular cholesterol production in cancer cells. Of course there are more ways for them to have access to that and this is why I developed this strategy https://www.cancertreatmentsresearch.com/reduce-cholesterol-in-cancer-cells-to-fight-cancer/
      I like Green tea as well, but I think a more effective approach to address glutamine is by addressing the mitocondria with mito inhibitors as we previously discussed https://www.cancertreatmentsresearch.com/a-list-of-mitochondria-inhibitors/
      As we also discussed in another post, phenylbutyrate may have other actions as well against cancer that may be more relevant compared to its impact on glutamine.
      Kind regards,

    2. Manuone, might consider fenofibrate.
      Very impressive! Fenofibrate reduced OXPHOS within 10 minutes of being applied to GBM cells!
      Certainly wonder what might happen if you were to first press glycolysis hard with say DCA and or other glycolysis inhibitors
      and then pulse fenofibrate.

      “Further analyses demonstrated that FF-induced suppression of OCR was immediate (less than 10 min), was dose dependent (Fig. 2C), and was accompanied by a corresponding increase in glycolysis (Fig. 2D)”


      Suggests that perhaps Vitamin C could replace 2-DG and then combine with fenofibrate.

      1. Dear Jcancom,

        Thanks for the contribution.
        Fenofibrate dont showed the same efectivity in vivo….
        I have to try to change the role of the therapy and I am clear that an option can be the metronomic dosages of vitamin iv and liposomal iv methylglyoxal.
        I’m going to start with IV salinomycin.
        I also have to change the cytotoxic, change temozolamide by lomustine. This is more toxic and I can not use it metronomically.
        -lomustine 40mgx3 days 1 time every 6 weeks
        -2dg metronomic 3 grs x 2 days
        -sininomycin iv once a week
        -vitamina c iv metronomic
        -methylglyoxal iv liposomal metronomic

        -simvastatin + ecetrol
        -sodium phenylbutyrate
        -mebendazole + fenbendazole
        -Omega 3
        -vitamin d3
        -complex vitamins b
        -liposomal curcumin
        -80mg aspirin ….
          My mother had an allergic reaction to dca I could not use it

        kind regards

        1. Dear Manuone –

          Have you looked at the tumor treating field devices made by novocure? The clinical trials for pancreatic cancer and glioblastoma both look promising (doubling survival median when added to standard chemo). I don’t know if any insurance covers it. The electric fields are low voltage sine waves, so although they rent their equipment for $20K a month this fundamentally should be a low-cost treatment.

          I will let you know if I start tinkering with a prototype device for my dad.

          I am rooting for you and your mother, and in particular that the liposomal IV methylglyoxal is profoundly effective in combination with the 2-DG.. I assume she is also taking cytomel along with the methimazole?

          1. Thanks for the information Jess!
            I was looking at some device of that type even in China. I did not receive an answer.
            The lack of time ends up being a problem for me 🙁

            kind regards

  4. Hola Daniel!! Felicitaciones por tu trabajo y dedicación. Tu ultima publicación nos ha renovado la esperanza en poder ayudar a nuestra sobrina que padece astrocitoma difuso. Vivimos en Argentina, en la ciudad de buenos aires. Podrías recomendarnos profesionales o instituciones que se adhieran a este ensayo. El.oncólogo que asiste a nuestra sobrina es reticente a cualquier terapia que no sea tradicional. Agradeceré toda la información que puedas aportarnos. Saludos cordiales. Carina

    Google translation:

    Hello Daniel!! Congratulations for your work and dedication. Your last publication has renewed our hope in being able to help our niece suffering from diffuse astrocytoma. We live in Argentina, in the city of Buenos Aires. You could recommend professionals or institutions that adhere to this essay. The oncologist who assists our niece is reluctant to any therapy that is not traditional. I will appreciate all the information you can give us. Best regards. Carina

    1. Dear Carina,
      Thank you. We are now working on finding ways to implement this approach in such a way that we will be able to answer questions like yours, and help the patients find trained centers on 2DG implementation. However, until that point, it can be used on compassionate basis by your current doctor, or a medical doctor that you find by yourself. Therefore, the best is for you to find a doctor in your area that is willing and is allowed to implement metronomic 2DG next to conventional therapies. Once you find him, you let us/me know, and from that point on things can move fast.
      Kind regards,

  5. This is super exciting! Metronomic is the way of the future … or continuous as it were. I don’t know if you were aware of this, but we developed a “Linear Elastomeric Pump” to make continuous IV more convenient (for example, places a long skinny pump along the same limb where the needle is inserted for a wholly self-contained solution). Additionally we have been developing some novel needle technologies for subcutaneous and extravisceral (tumor adjacent) infusions of chemo agents like this. Stay tuned. Sounds like a match made in heaven. Also recent studies demonstrating these therapies are concentrated locally using ultrasound and TENS therapy directed at the tumor site. The machines to do this are quite reasonably priced, especially on a rental basis. Best of luck! Expect to hear good outcomes from this.

    1. Thanks! You can add the links to the pumps and needs here. I will not consider them as advertisement.
      Can you please explain what do you mean by:
      “Also recent studies demonstrating these therapies are concentrated locally using ultrasound and TENS therapy directed at the tumor site. The machines to do this are quite reasonably priced, especially on a rental basis. Best of luck! Expect to hear good outcomes from this.”?

      1. Hi Daniel –

        Our pumps are not yet available but that shouldn’t stop people from doing the treatment. For elastomeric pumps the halyard homepump is the industry workhorse. A number of sources can be found online with a quick websearch: https://www.google.com/search?q=halyard+homepump&tbm=shop
        When purchased in quantity of 24 the can be had for just around $13 each, and even less in quantities of 48

        As for the ultrasound and TENS tech, I have an ultrasound that I’ve purchased cheap for evaluation. Here’s about 20 articles on the subject: https://drive.google.com/drive/folders/1iUOR21sBHBJ9kIwBIG3o98GGHQxlCSPw?usp=sharing

        One study (the one on gliomas) demonstrated a 6-8 fold increase in the absorption of nanoparticles by the tumor when subjected to ultrasound.

    2. lullabyman, you are so right this is SUPEREXCITING!!!

      It is such a simple idea that it almost has to work!

      It would be super awesome if this thread and much of the rest of the cancer treatment infrastructure could converge on this idea.
      If we could lock in on an cancer effective treatment, then we could finally remove much of the noise that people need to work through and send them directly to something that will be effective for them. Perhaps D might consider reorganizing this site so that people are channeled through the Metronomic Treatment idea on page landing. This will be especially important as more positive patient reports emerge.

      Shutting off energy supply to cancer cells and doing this over a prolonged period of time should have very very potent anti-cancer effects. There are a range of cancer treatments that could be used for this purpose including Vitamin C, 2-DG, methylglyoxal etc..
      While 3-BP could be highly effective in such an approach, it might be perhaps best to stay with the others as they might be safer.

      lullabyman, do you have any articles that show Vitamin C ATP depletion through time? I would be especially interested in those that used metronomic dosing. Has metronomic iv vitamin dosing been done in vivo? Might you be aware of clinical results or at least patient reports of metronomic iv vitamin C dosing? I believe I did encounter an anecdotal example of prolonged vitamin C dosing online with a large response. Has metronomic iv vitamin C dosing been shown to be safe in humans?

      Here is the posting from the Vitamin C thread when we discussed this idea last year.
      As soon as you explained how the Scottish Vitamin C results were likely a result of the duration schedules used, a bunch of light bulbs went off for me. It was then fairly clear to me that a duration dosing strategy should be a highly effective anti-cancer strategy. Knowing that this is officially called “metronomic dosing” can let us access the existing research literature.


      April 13, 2017

      “… In terms of treatment duration [in relation to iv Vitamin C], has there been reports where they could maintain within the mM range over extended periods of time (perhaps even days?).”

      October 10, 2017

      “Good question. … A dozen studies now demonstrate that the main cancer killing mechanism is by NAD depletion, or in other words cancer is starved to death. This explains how Pauling was able to get such great results: when starving something to death the critical parameter is not dose but time. … It is also important to note that the tumor response with his low-rate but long duration protocol was so pronounced that a number of patients experienced tumor lysis ( sadly resulting in death). Although sad, it dos demonstrate once again that dose is not the critical factor. .. [A large iv vitamin C cancer centre] have never seen a tumor lysis in the history of the centre [perhaps due to non-duration dosing?]. It means that with patients with heavy tumor load will probably not be candidates for our pump, not until the bulk of them are removed, and then administration rate wold be especially slow to start with.”

      Then it seemed to take me about a month to fully process lullabyman’s comment:

      November 14,2017
      “Oh MY!!
      …. ARGGH!”

      This is extraordinarily important!
      Even simply stopping glycolytic cancer cell overdrive with metronomic ATP depletion (without addressing OXPHOS concurrently) would be of substantial help. Pushing cancer cells to OXPHOS, to a certain extent normalizes them. Add in OXPHOS inhibition and things are even better!

      Look at Figure 1b, 2c and D, and 3 in below article! Even 48 hours of dosing can result in very large reductions in viability, ATP, lactate, HK II etc. PMID: 27163639

      Others now are also thinking in terms of metronomic metabolic treatment.
      Here is a methylglyoxal metronomic dosing study!
      Look at Figure 1a, and B. This one goes out to 120 hours. Simply using 0.2 mM MG over 5 days nearly gives you 50% reduction in cell viability.

      It was somewhat disappointing though that when they went in vivo MG metronomic was not enough! (Figure 10A).
      Seems somewhat surprising to me. It could just be there setup. I would have guessed that merely consistently pressing ATP depletion would have done it. Yet, D does note that you need more of a stress ( with OXPHOS inhibition etc.). When they added in chemo, they stopped cancer growth! PMID: 30170097

      I wonder why they did not instead use their existing MG treatment plan which includes oral Vitamin C etc. Also would be very interested to see what might happen if one were to replace MG with nanoMG!

      1. lullabyman,

        what would your dream implementation of metabolic metronomic dosing look like?

        There are a range of ATP lowering agents available; it might be best to rotate through some of them to see
        which of them were most effective. This would also reduce potential for side effects.

        Any suggestions for formulations? Delivering the agents directly to the cancer cells with chitosan etc. would
        be an elegant way to enhance effectiveness and lower risk.

        I am very interested in hearing your suggestions for combos for metronomic vitamin C. Also would like to know what you meant by ultrasound add-on. What would be your ideal metronomic protocol?

          1. lullabyman, your blog comment is right on the mark!
            I am super excited and I hope that others of the forum also see the potential.

            Thank you for taking the time to consider my question in such a formal and thoughtful manner. The internet age has allowed people the opportunity to bang away on their keyboards and often transmit their unprocessed thoughts to a global audience. It is always gratifying when someone steps back and writes a considered reply.

            The entire concept of metronomic dosing (and more particularly metabolic metronomic dosing) is finally starting to congeal for me and hopefully for others on forum. It is simply beyond my comprehension how the words “metronomic” and “metabolic” have until now somehow not been put side by side before or possibly hardly even imagined at all. When I lurked around pubmed, I found a paucity of related literature. Is it really conceivable that the greatest threat to our greatest threat was someone asking “What if…?” ?

            When will patients finally realize that if they do not ask such questions and allow themselves to be treated with protocols that are entirely lacking in basic common sense that the result will be yet more TailorXs? The follow-on question for me obviously is: If chemo were ineffective in 85% of early stage breast cancer patients, then how could it be expected to be effective in later stages? What about all the other hundreds of thousands of other early stage patients who are likely on the same treatment plan? Is there even research underway that is addressing this question?

            The conversations that we have had about the power of duration dosing (metronomic) are still as eye opening for me now, as when you first revealed the concept. Right away– the first time you filled in the blanks for me– the sky opened up for me and transcendent truth was before me!

            These powerful folk wisdoms are self-apparently credible and very likely correct. For example (roughly), “when starving cancer cells it is not dose that is important but instead duration”. This statement should to most of those on our thread almost be read as a tautological truth. It is true because it could almost not be not true.

            The quote below is eerily and profoundly true. The mistake of thinking in terms of maximum tolerated dosing is almost hardwired into deep human psychology. Often real breakthroughs and real genius only occurs when people finally ask the question: What if it isn’t what we have always thought it had to be?: What if it’s the opposite? People want to see the big hit against cancer, when what you likely need is an ongoing continuous force that knocks it down through a prolonged time.

            This one revealed itself to me when looking at Don’s chart. The real power of his treatment program was with the ongoing effect of his diet program than with a large single hit. It is quite startling to realize that MTD approaches might only give you on the order of an hour per day of therapeutic effect. The real question people should ask themselves is: How could such a dosing approach possibly be successful, even if the treatment is known to be effective? It is known that cells (including cancer cells) have a range of short term responses that are on constant standby to counteract almost any threat (pulse threats). These pulse threats are everywhere! How likely is it that in our evolutionary history that long term threats would be as prevalent (press threats) and of more importance that mechanisms would have evolved to defend against them {ironically, the big example of a press counter-response that springs to mind is ketogenic diet which is unsurprisingly a long term survival strategy that has significant anti-cancer potential}?

            “When cancer wins it happens in between the cancer-killing treatments. Always. It’s that simple. The battle against cancer is decided in the spaces between conventional treatments, not during conventional treatments themselves.”

            As a first approximation of a basic mathematical formulation of the effect of metronomic dosing perhaps:
            Effect = Dose * [e ^^ Duration] would suffice. To add more realism, we could add in the dual effect of OXPHOS and glycolysis: Effect = Dose(ox) * [e ^^ Duration(ox)] * Dose(gly) * [e ^^ Duration(gly)]

            From the conversation on the vitamin C thread, I can see the connections for:
            https://www.ncbi.nlm.nih.gov/pubmed/?term=30170097 and
            https://www.cancertreatmentsresearch.com/a-new-approach-to-improve-effectiveness-of-cancer-therapies-is-getting-ready-to-begin-human-trials/#comment-7838 (this thread)

            In Press-Pulse, if you replace “Press” with “metronomic” the approach moves into much greater focus for me

            E260 could finally conclusively demonstrate the effectiveness of metabolic medicine and more particularly how effectiveness could be amplified by glycolytic metronomic stress. What happens when the effect of this treatment is a constant raised to the power of the duration? I will leave this as an exercise to the readers to contemplate. Selectively and effectively stopping OXPHOS and glycolysis in cancer cells should mean a profoundly profound metabolic hit. The entire cupboard of metabolic treatments that we have discussed on the forum would then have greatly enhanced potency.The trial is expected to start roughly next April. Patients might need to be told that optimizing with glycolytic knock down could rapidly lead to TLS.

            A promise was made to our friends on this forum and the compass that through our combined efforts we will discover and help to manifest a treatment that will help others who are now on their own cancer journey. Considering the intractability and, yes, the seeming eternal persistence of metastatic cancer, such a wish might have been regarded as hopelessly optimistic not so long ago. However, the metronomic metabolic approach is so intuitively logical and potentially powerful that this idea could discharge the obligation: A promise made will be a promise kept. The results that D is already tentatively disclosing suggest that the promise will be kept.

            1. What is interesting is that this strategy, and it’s efficacy has been known for quite some time. Michael Retsky, who is on my SteadyPivot team, cured himself of cancer using this strategy some 20 odd years ago using cheap (out of patent) chemotherapeutics. He simply used a TPN pump with a PICC line, and a bag that he filled himself. Now, it did take him over a year to do this, but he was able to lead a fairly normal life at this time. He has since become an advocate for a number of low-cost cancer therapies with the goal of $1/day to cure cancer, and earlier this year was highly instrumental in getting the FDA to finally approve the recommended treatment to put cancer patients and survivors on daily low dose anti-inflammatories which has consistently demonstrated a 20%-30% increase in life expectancy.

              A group of French doctors (most not oncologists, unsurprisingly), headed up by Nicolas Andre’, have been advocating for a metronomic approach in 3rd world countries for years now due to the high value / low cost / but this approach has met with little acceptance. You can read more about their efforts at metronomics.org. Here’s a good video he did: https://www.youtube.com/watch?v=d9VLJ_fGLMI

              He is focused mainly on doing it orally, which is great if you can get it to work, but current chemo agents aren’t quite there yet. Maybe we’ll get lucky though and can make that happen, but I’m afraid that right now oral metronomics dances on the edge of marginally better that it’s not really going to revolutionize cancer treatment.

              Andre’ talks about an interesting concept about cancer, and it’s one that Dr. Hunninghake at Riordan Clinic, a partner of mine, has a sympathetic ear, and that is that cancer is a part of life, and the “cure” if there is to be such a thing, needs to be respectful of that fact. In that way cancer is not a thing to be destroyed, but controlled and minimized, and the patient empowered to keep it at bay, which they’ve likely been doing all their life until it got out of control. Cancer, in that way, is more of a verb than a noun. And metronomics or continuous treatment is a more suitable strategy within that paradigm. If you kill off all cancer, and cancer keeps the body’s resistance vigilant, then does that resistance get lazy until recurrence metastatically happens all at once, everywhere? Seems to. In truth, we probably have DNA mutations all the time from birth … many of the time resulting in uncontrolled growth (cancer), but in our youth we efficiently keep it in check. So it only becomes a problem when the burden on our systems is overwhelming and it’s allowed to go haywire. Immunology oncology seems dependent on this principle.

              I think conventional oncology may be scared of metronomics because it can, in fact should be, done mostly at home … and expensive chemo is no better than cheap out-of-patent chemo, so fewer visits? Fewer expensive treatments? And if it works well enough then there may be fear that other profitable treatments will be found superfluous. Personally I’m certain that won’t happen … cancer is a beast, and what we know of metronomic therapy targeting metabolics is that for aggressive cancers it is not enough. You have to at least have something that directly attacks cancer too, target angiogenesis (IVC does this, incidently), strengthen’s immunity, etc. Much of that can be done metronomically though. This is what Andre’ calls Metronomics 2.0. Doing it for maintenance is Metronomics 3.0.

  6. Daniel,
    I could not be prouder to read this news. Congratulations – this is just reward for your tirelessly good, and humble, work in this field. I’m so looking forward to hearing news of the trial as it progresses. We know that it’s so easy to get carried away with potential treatments, but with each trial we learn more (even if it’s just ‘well, that didn’t work’) You are contributing so much to this field.
    I recently came across another case whereby the marker for scans (in this case for my own cancer, prostate, has had remarkable effect. You can see them in this image, which I believe has won an award for best cancer image of the year: http://www.snmmi.org/NewsPublications/NewsDetail.aspx?ItemNumber=29483

    I really have to make time to do that interview with you before the year ends!

    Congratulations, Daniel – Mihaela would be so proud.

    1. Dear David,

      So nice to hear from you again and thank you so much for your words and thoughts of appreciation.

      I very much think and feel the credit goes to the many other people involved during the past years in one way or another: The patients and their caregivers doing more than the average. The medical doctors and related clinics or hospitals doing much more than the average. The academics (such as Prof. Lampidis and dr. Metin, and many others) doing much more than the average. The contributors on this website not only thinking but also sharing their thoughts to help others. And of course those supporting the existence of website and related activities like this with their kind donations – and with that I like to thank you again as you were the first to support this website! 🙂

      Yes, most of those like the visitors of this website and like us, searching for solutions and going beyond the “limits” of what is generally known and accepted, we have the tendency to keep searching even after we may have found good solutions. We need to put a lot of energy and momentum in taking this approach, and due to inertia is more difficult to stop when we find relevant solutions. I think that until we have better solutions, metronomic 2DG is a unique tool that should be considered as part of nearly all treatment strategies. This is why I decided to make a stop here and help bring it under the spot light. And the nice thing is that there is now more and more evidence/facts supporting this view.

      What is important for all of us to understand is that until we do not completely understand the origin of cancer (or various forms of cancer), we should build strategies involving multiple tools to attack the major weak spots of cancer cells. This is where the industry also moves now, and that is reflected by so many combo studies emerging during the past years. And this is where metronomic 2DG contributes as it is addressing an essential soft spot of cancer cells related to their need for high amounts of glucose during the fast division and during the fight with conventional therapies. I actually think that the industry should see the opportunity here, as such approaches can help make the pharma drugs work again.

      I will check the link and it is always a pleasure to speak with you, David!

      Kind regards,

        1. Thanks J. I’ve seen the paper when that was published and I like it.

          The advantage of restricted-KD is indeed two fold:
          1. higher 2DG dose can be applied while possibly reducing side effects
          2. lowering the blood glucose levels, the tumor will be more avid for glucose and thus will absorb 2DG better.

          The challenges related to this idea:
          1. restricted-KD is difficult to achieve for most patients
          2. to maximize this concept we would still need to address the challenge related to the high insulin release following high dose 2DG admin … unless we would also use another drug to reduce the insulin release or inhibit insulin receptors prior to and during the application of high dose 2DG.
          3. hormonal cancers or dose relying more on respiration would not do well on KD
          4. side effects of higher dose 2DG, higher than used so far, it is unknown at this point

          Therefore, to avoid some of the above risks and benefit from this concept, what we can do in my view is one or a combination of the following:
          1. use restricted-KD when possible with the current metronomic-2DG aproach (and not with a higher 2DG dose)
          2. to further enhance this or alternatively to reduce blood glucose levels, use Metformin (which also adds value from the mito inhibition point of view).

          Note that Marco’s wife was (and I think she is still using that) on KD while also using 2DG and others treatments and while obtaining continuous positive results. Nevertheless, other patients with positive results were not on restricted-KD (but most used Metformin at the RIGHT timing according to own treatment schedule). Therefore, while metronomic-DG seems to help effectiveness of chemo regardless if the patient is on restricted-KD or not, restricted-KD could further add value to this concept. Finally, it’s about what the patient feels it works the best for him/her, but the low sugar/carbs should anyway be a basis in any treatment strategy.

          What do you think?

      1. Please do not thank me for being the first to support the website – I considered it a great opportunity to help in a field (people powered innovation) that I passionately believe in.

        More when we meet in person!

  7. Estimado Daniel,

    Gracias por tu pronta respuesta. Uno de los problemas que enfrentamos es la dificultad de encontrar algún profesional dispuesto a aplicar cualquier tipo de terapia o tratamiento que no sea el tradicional. Que hacer? Hemos hecho consultas sin resultado alguno . En buenos aires habra algun centro o profesional que estudie esta enfermedad? Gracias nuevamente por tu tiempo.

    Google translate:

    Dear Daniel,

    Thanks for your prompt response. One of the problems we face is the difficulty of finding a professional willing to apply any type of therapy or treatment that is not traditional. What to do? We have consulted without any results. In buenos aires will there be a center or professional who studies this disease? Thanks again for your time.

    1. Dear,

      Very interesting coincidence:
      last evening I was speaking with a man who informed me about a clinic in Argentina that is giving 2DG to their patients. Here is the clinic https://terapiametabolica.com and here is one of their paper http://www.clinicsinoncology.com/pdfs_folder/cio-v3-id1512.pdf
      So the great news is that you can have access to 2DG in your country and given in a professional environment (as it seems from the website of the clinic and published articles).

      However, please note that to my knowledge, when they use 2DG they do not use it in metronomic way (which is the way it should be used) but it is used in the old approach (bolus).

      So what I think you could do if you want to start using 2DG metronomic is the following:

      1. contact the clinic in Argentina and ask if they have a medical doctor willing to give you 2DG metronomic
      2. If they agree, you let me know and I will give you the e-mail of Prof Lampidis
      3. Next, the Medical Doctor in Argentina is contacting Prof Lampidis for treatment protocol of metronomic 2DG
      4. After they receive that, I can speak with your doctors on best practices regarding the implementation of the protocol within a larger treatment strategy (that will include also some re-purposed drugs)

      Please let me know if this is clear or you need anything else.

      Kind regards,

  8. lullabyman, very interesting video!

    I was surprised when he mentioned the mathematical modeling study as I had read that article and had found that approach very powerful. Having in silico predictive ability is very impressive.

    The video also confirmed my reading of the literature as focusing most of the metronomic definition on angiogensis and chemotherapy. You noted that metabolics might simply be insufficient, though that does seem to be the focus that is ongoing now with metronomic 2-DG. This forum’s metronomic variant might be somewhat unique, though the recent MG metronomic article also combined with chemo. Shutting off metabolic pathways through time still feels to me as though it could be a very powerful and largely non-toxic treatment approach.

    The final section on chaotic theory was a true eye opener. I had thought some of the treatment schedules that I saw on this forum looked a little messy and I thought perhaps we should try to clean them up. The video noted that there is a strong rationale not to have everything lined up in straight rows and columns: Cancer surely is not a neat freak.

    As you mentioned on your webpage, the maximum tolerated dosing approach has a very weak logical basis. What happens during all the time that patients are recovering from their treatment? It can be much better to hit softer but more often.

    What do you think of my last post on the 21st Century treatment forum page? Does glycol actually have the NAD depleting effect that I am claiming it does? It is pretty remarkable to me that a mere 1 cc or so a day of it could have such drastic effects on cancer. I was thinking that one might need to take more like a up of it!

  9. Good afternoon,

    First of all, thanks for your investigative work, it’s such a luck to have found your web. The only real hope after many months of darkness, lost in the traditional medical system.

    I would like to ask you if you know any doctor or place where te 2DG therapy is going on in Switzerland. My husband has a cholangiocarcinome intrahepatic and it’s not responding to the chemotherapy. It’s one week now since I discovered this web and we started making changes (KD, supplementation, and soon hypertherm and vitC). We live in Geneva, but we’re open to go further if necessary.

    Thanks again.


    1. Dear Maria,

      Thank you for your comment.

      Regarding the clinical trials, we are working now on the process behind but that takes some time to put together and we also need to find the financial support.

      Fortunately there are countries where its allowed to be used even if all the clinical trials are not yet done as long as the toxicity profile is clear and there is enough scientific evidence. In this context, I am in contact with patients from Germany who convinced their doctors at conventional hospitals to support with metronomic 2DG next to conventional treatments. One option would be to get you in contact with the patients. The other option would be to connect you with private clinics willing to help. Please let me know which way you want to start and I will send you and e-mail to connect you with the relevant people.

      Kind regards,

      1. Good afternoon Daniel, and thanks for your quick answer.

        Yes, I’m interested in getting in touch with those patients. I don’t know if the 2DG traitement is allowed here in Switzerland but that would be great to talk to them to know how do they managed to convince their doctors.

        Even so, I’m also interested to have a look into private clinics. I’m Spanish so we’re opened to search for a treatement in my country. I’m not sure at all that we can afford it, but at least we have to try.

        Thanks again for your help and for letting us gain time.



        1. Dear Maria,

          The best would be to find a way to convince your doctor to support with this. I will connect you with two different Spanish patients from Germany who may be able to give you ideas on how to convince your (conventional) oncologist.

          The other options is the private clinics such as those mentioned my Marcos. The cost should be affordable given that the 2DG material cost for one days treatment is about 30 euro. Adding all the other costs and required profit of a private clinic it should probably not cost more than 150 euro for one day of 2DG.

          Kind regards,

    1. Good afternoon Jcancom,

      Thanks for your answer.

      Unfortunately we can’t go so far. We’re considering the options but we don’t really even know if we can afford a private traitement.

      Can we ask you why do you consider 3BP instead of 2DG?



  10. MariaR,

    It is more: 3-BP and 2-DG than 3-BP or 2-DG.
    D, found that an extensive range of treatments were needed with an ongoing attempt to find better combinations and other drugs.

    Metronomic 2-DG certainly does appear an attractive option. From all of our discussions on this forum and on the cancer compass forum, metronomic metabolic dosing has a strong theoretical rationale. My inclination would be that you should at least try metronomic 2-DG if not other metrononics metabolics (possibly concurrently, though I would tend to stay away from 3-BP metronomic).

    With 3-BP, I am especially impressed with Dayspring. They have reported many impressive patient testimonials. It appears that they have been able to find ways to potentiate 3-BP in ways that has largely eluded the best efforts of many on our forum. 3-BP is a very powerful anti-cancer drug (perhaps the most powerful anti-cancer drug ever discovered) as long as the MCT-1 portals are open cancer would be unable to sustain prolonged treatment.

  11. Dear Daniel,

    Thanks again for your contributions to improve therapy.
    I will detail the drugs I use is practically the same treatment schedule that I sent you a few weeks ago ……..


    -TEMOZOLAMIDE 80mgx3 days (I think it has not been entirely effective) I will try LOMUSTINA (the official dose is 100-120mgxm2 every 6 weeks, try 40mgx3 days every 6 weeks). Lomustine is more toxic than tmz I will have to be careful with platelet counts. I can not use it metronomically only 40mgx3 every 6 weeks
             * 3 days of chemo together with TETRANDINA LIPOSOMAL

    -METFORMIN 1700mgx5 days one dose at night)
    -QUETIAPIN 20mg at night
    -NAPROXEN or CELEBREX every day (naproxen interacts less than celebrex with other drugs)
    -MEBENDAZOL 500mg x 5 days
    -FENBENDAZOL 500 mg x 6 days
    -SODIUM PHENYLBUTIRATE 4 grs. x 5 days
    -TALIDOMIDE 50mg at night
    -TAMOXIFEN 40 mg x 5 days
    -CANAGLIFLOZIN 100mg x 2 dias
    Possible to add:
    -TRANILAST 300mg (I find it very interesting but I do not find too much interaction information with the rest of the drugs)


    -2DG metronomic for 2 days (try to use it in chemo days)
    -VITAMIN C IV metronomic:
             * My idea is to use 100ml in an elastromeric pump at 3 ml / h. Administer 50 grs in 33 hours (1.5 grs / h)

    -SALINOMYCIN IV 1 day a week escalating dose up to 10mg target dose

    * Other iv could be taurolidine (although I would not use other iv for a week).
    Diflunisal, 3bp (risk of edema) or NIVOLUMAB (has not shown a high effectiveness in gbm but we would have to see if it improves its effectiveness in a cocktail like mine, maybe if, although I do not know the interactions)

    I am aware that given the situation I have to take risks. This is the list of interactions that I find:

    https://www.drugs.com/interactions-check.php?interaction_list_id=183194368&drug_list=3465-0,1062-0,1535-0,1573-0,1750-0,1979-0,2067-0,2092- 0.2154-0.243-3197,1690-1051,2145-3709,2176-1424,86-0,2216-14576


    -OMEGA 3 2grs day
    -HCA 1800mg

    This is the most powerful treatment I can currently access. The biggest part is thanks to you Daniel.

    I have the feeling that it is not crazy to put a glioblastoma in remission, even if it is advanced … knowledge and God are on our side ……..

    kind regards

    1. HI Manuel,

      The priority for me would be to build a coherent strategy. So that even if there are drugs that may be very relevant, if we really need to take out some in order to add more along the strategy, I would take out those that are not part of the specific strategy.

      In my view, one of the essential strategy in GMB is related to the fact that GMB is known to be very glycolitic. This is why I would build the strategy such that will address that aspect as good as possible. Having this in mind, here is how I think:

      – Metfomin – has high priority as a part of the metabolic approach and pH approach (even if it is increasing glycolisisi it will decrease blood glucose levels and will address the cancer cells relying on respiration – using Metformin, means we also need to make sure we add glyco inhibitors)
      – QUETIAPINE is a good one but we can remove if we need to make place for another better drug – therefore, this drug has medium priority
      – Ezitimibe – medium priority as it is part of the cholesterol approach (which is good but this is another strategy)
      – Statin – medium to high priority as it is part of the metabolic, pH and cholesterol approach
      – NAPROXEN or CELEBREX – high priority due to anti inflammation action that is important specifically for brain c patients
      – Mebendazole/Fenbendazole – high priority but would use only one of them instead of two at the same time (e.g. one week one and the other week another one) to make space for more drugs
      – SODIUM PHENYLBUTIRATE – high priority due to relevance to brain c patients (is may act like DCA)
      – Thalidomide – medium priority (although good for anti angiogenesis effect)
      – Tamoxifen – high priority (multiple actions)
      – Aspirin low dose – high priority (anti inflamation)
      – CANAGLIFLOZIN – high priority (anti glycolisis)
      – Supplements you use are very good in my view

      Therefore, based on the list above you could remove QUETIAPINE, Ezitimibe, Thalidomide. That doesn’t mean they are not good, it’s just making choices given the limitations. We could always start them again at a latter point.

      By removing those, I would make space to introduce:
      – Acetozolamoide or TOPIRAMATE to address CA IX (pH strategy)
      – Stiripentol which is a LDH inhibitor (metabolic strategy) https://www.cancertreatmentsresearch.com/a-list-of-mitochondria-inhibitors/#comment-7986
      – Syrosingopine would be great to inhibit MCTs but this is difficult to find https://www.ncbi.nlm.nih.gov/pubmed/30540938

      Of course, if we feel that things are going right as used now, I would not change anything.

      But it’s important that we keep in mind the profile of GMB as highly glycolitic and the fact that we now know and have tools to influence that. I like cholesterol strategy a lot but I think its important to be stronger on the metabolic line, that is why some of the drugs from the list above and part of the cholesterol strategy have lower priority – it’s all about the context and limitation of nr of drugs we can use.
      From a metabolic point of view, the drugs in the list above are doing the following:

      – Metformin (mito activity lowering and blood glucose lowering),
      – Statin (MCT lowering).
      – Aspirin (MCT lowering),
      – Mebendazole/Fenbendazole (GLUT1 lowering)
      – Sodium Phenylbutyrate (activate mito if not the case)
      – Tamoxifen (fibroblast lowering if any in brain c – they are suppliers for fuel)
      – Canaglifozin (glucose transport lowering)
      – Omega 3 may lower Na/H exchange

      If glycolisis is still active, Acetozolamoide will help to acidify the cell when using glyco so it can be killed. https://www.cancertreatmentsresearch.com/ph-cancer-a-top-treatment-strategy/
      And Stiripentol will try to stop glycolisis somewhere at a downstream level.

      Tranilast, I like it a lot but maybe Tamoxifen is enough to address fibroblast (in brain c the existence of fibroblasts is a little debate, in literature).

      Manuel, I hope the above helps!

    2. Hi Manuone,
      what a powerful treatment indeed!

      About Thalidomide. In a mouse model, thalidomide wasn’t effective against gbm, yet when used in combination with Tarceva it did prove effective:

      The mice were treated once a day for 10 consecutive days. The drugs were given orally. A series of images revealed no tumors in mice after 20 days.

      “This could be a new effective treatment for GBM,” Habib said. “EGFR is expressed in the majority of GBM tumors and drugs are available that can inhibit EGFR. However, EGFR inhibition is not effective in this tumor. We found that inhibiting EGFR leads to increased secretion of TNF and activation of a survival pathway in cancer cells. A combined inhibition of EGFR and TNF signaling inhibits tumor growth. Thus, we have identified a way to make EGFR inhibition effective in this tumor.”



  12. Hi Daniel and people:
    A year passed since my last post, a year ago passed my brother, what a fear to come here, after so many hours and so many papers .
    I am gland Daniel, that your proyect is taking form, and i hope can help the people.
    Many writen , i will read all new.


    1. Hi Jandro, I hope you are doing well. Was that a fear related to memories? If I remember correctly, you are on the way to become a medical doctor? Whenever you find something relevant in this field, please share with us here too. Kind regards, Daniel

  13. Hello guys!

    At the moment my mother seems to be stable even with some improvements :). We are going to rehabilitation sessions that seem to improve their motor condition.
    I have strengthened the therapy since December, increasing to 2 cycles of 2DG metronomic, salinomicin iv and 2 cycles of vitamin C iv
    I added canagliflozin every day (except 2DG days)

    – Tetrandine liposomal + 100mg temozolamide x 2 days (maybe I should change to lomustine soon)
    -metformin 1700mg
    -sodium phenylbutyrate 4 grams
    -tamoxifene 60mg
    -celebrex / naproxen

    some supplements: omega 3, vitamin d3 , silmarin milk thistle and boswellic acids

    infusions: 2DG metronomic, iv salinomycin and vitamin c iv (2 times per week)

    Studying several weeks many different studies I have come to the conclusion of the effectiveness of REGORAFENIB
    It has shown effectiveness in clinical trials doubling the average survival,



    https://www.healio.com/hematology-oncology/neuro-oncology/news/in-the-journals/%7B79518212-6aca-4fce-875f-d207b28ede2e%7D/regorafenib-confers-substantial-survival-benefit-in -recurrent-glioblastoma

    It is a multi-kinase inhibitor that usually has a lot of side effects in a very high percentage of patients, this worries me.
    Skin reaction hand foot, callused and painful formation …
    Hepatological alterations (alt)
    Risk of bleeding
    Increase in lipase
    These would be the main ones (within many more)

    The dose is usually 160mg x 3 weeks. I have read that recently it is recommended smaller doses and go up progressively.
    It is possible that within a “cocktail” approach you can use lower doses. On the other hand I read that the minimum effective dose they consider is 80mg ……
    I believe that multi-kinase inhibitors are potentially effective “weapons” although they are not free from severe side effects. I am sure that you have studied these drugs and I would like to know your opinion.

    These are the new drugs that I think I could add to the therapy:

    BERUBICIN (intravenous)
    Maybe an ecct device and returned the nanothermia sessions later …..
    I will appreciate your opinions and advice infinitely

    Kind regards

    1. Dear Manuel,

      It’s great to hear that your mom is stable and maybe possibly even improving! This is in contrast with a generalized progression report of one year ago and it suggests you are on the right track. Keep up the good work! I will check the list of drugs you are considering and give you my opinion but since you are seeing positive signs with the current approach, I would be careful with changing too much at this point.

      Kind regards,

          1. Thanks for the contribution Johan!
            I knew the virtues of luteolin to inhibit autophagy and its synergy with milk thistle.
            The problem with natural supplements is always their poor bioavailability even with a large intake of capsules. in vitro and murine studies with concentrations that are difficult to reach in humans.
            Of the natural molecules luteolin seems the ideal to avoid the use of hydroxychloroquine which I never dared to use.

            kind regards

            1. Very true, but when you’re combining many drugs and supps, you can potentially get an edge even if at lower doses, especially if synergies are at work.

              Have you looked at disulfiram?

            2. Dear Manuone

              It seems that luteolin also attenuates anti-apoptotic proteins in BCL family, like others in polyphenols listed below:
              The overexpression of BCL-2 was found to be related to the progression of cancer and also providing resistance towards chemotherapeutic treatments. In the present study, we found that all polyphenols (apigenin, fisetin, galangin and luteolin) bind to the hydrophobic groove of BCL-2 and the interaction is stable throughout MD simulation run.

              Which one of these are best in your opinion?

              Thank you

          2. Hi @Johan

            I´m looking for IGF 2 and i think luteolin can be helpful .

            1-Can i ask you if you know any reliable extract other than smart brand?
            2- How much should you take to have some desirable effect?
            3- Can i know if you know more supplements/drugs/strategies for this purpose? I have read that lymphomas uses more IGf- 2 and i don’t find easily info about this approach … Fasting is a good idea but i would to know more about reduce this pathway 🙂

            Thank you for you patience

            Kind regards


            1. Hello Iñaki!

              I’d take an artichoke supplement (1 gram) and include oregano and radicchio in your diet. Synergies with IP6, ECGC, Ursolic acid.


  14. Manuone, I am so glad that you found this helpful and are investigating the idea further!

    GAPDH is THE pivotal point in glycolysis.
    For each glucose molecule, cells invest 2 ATP to reach GAPDH.

    Stopping glycolysis results in the cancer generating negative energy.
    It is not hard to see that this might be the primary reason that 3-BP can have such dramatic effects on cancer cells.

    GBM is known to be a highly glycolytic cancer, so KA might be a useful treatment for it.
    It is disappointing, though, that the research is only starting to warm up.
    I have not been able to find any combos in the literature (with 3-BP they have reported quite a number).
    Given this one could only guess what might help.

    Perhaps shikonin through PKM2?

    Best Wishes, Jcancom

  15. Thanks for the information guys!
    Johan the study is very interesting. I am concerned about the cancer’s ability to obtain energy through fatty acids as an alternative to glucose reduction
    The drug ORLISTAT for obesity can be a good tool in this process.

    Jcancom, the problem is that koningic acid is not accessible. It is very expensive (€ 300 × 1mg). It is not sufficiently tested in humans.

    kind regards

  16. Hello friends!
    I contacted a laboratory to make MitoHonokiol. They are working on it and I hope to hear soon.
    I have been studying it carefully and I think it has great potential.
    I have to thank Jcancom’s mitohonokiol publication that made my interest awaken 🙂
    It can be a very relevant issue and I would like to discuss it with all of you.
    It would be very interesting to comment on everything related to dosage, administration time and compatibility with the other treatments.

    Thank you all

    1. That is great news. Could you ask the laboratory if they are able to make Mito-Metformin? Quoting from an article:
      “1000-fold-higher potency of mitochondria-targeted metformin”
      Mitochondria-targeted metformins: anti-tumour and redox signalling mechanisms. PMID: 28382202

  17. @Daniel: I suggest to read this paper, since it may help increase the efficacy of 2DG + Metformin, especially against tumors with a high percentage of CSCs.
    Survival of Cancer Stem-Like Cells Under Metabolic Stress via CaMK2α-mediated Upregulation of Sarco/Endoplasmic Reticulum Calcium ATPase Expression. PMID: 29279319
    Their results show that CSCs are resistant to metabolic stress (DG + Metformin), and a main mechanism of resistance is the activation of SERCA (Ca2+ ATPase), which prevents Calcium overload. About 7 months ago Jcancom mentioned a link between 3BP and Calcium overload in pancreatic cancer, in the comments to your article (this page).
    By inhibiting SERCA with Thapsigargin, together with 2DG and Metformin, the tumor growth is strongly inhibited in mouse models. Now, Thapsigargin is too toxic to be used in humans, but there are prodrugs, like Mipsagargin, which undergoes clinical trials. Other drugs, which can lead to selective Calcium overload in cancer cells, may be used instead of Mipsagargin, assuming the vulnerability to Calcium overload is generally valid under metabolic stress. Possible candidates (so far, what I found) are Trifluoperazine and Mibefradil. Inhibitors of NFkB may also help, since active NFkB activates SERCA.
    It may be worth reading an article on Calcium signaling in cancer. Targeting calcium signaling in cancer therapy. PMID: 28119804
    Some tests of 2DG + Metformin, in combination with other ion (Na, K, Cl) channel disruptors could provide valuable new information. Article: Membrane-Depolarizing Channel Blockers Induce Selective Glioma Cell Death by Impairing Nutrient Transport and Unfolded Protein/Amino Acid Responses. PMID: 28087597
    It would also be interesting to try 2DG + Metformin + Bedaquiline (an antibiotic) to inhibit cancer cell metabolism.
    Antibiotic bedaquiline effectively targets growth, survival and tumor angiogenesis of lung cancer through suppressing energy metabolism. PMID: 29107691

  18. Great article Ovidiu is very interesting. Improving what we already “have” seems to me a key piece.
    I appreciate very much all the contributions you make just like Johan, Jcancom … etc
    Currently I have tried to improve the action of 2 DG metronomic with fenbendazole + metformin + DCA + doxycycline + tanoxifene + sodium phenylbutyrate.
    I think they make an important synergy.
    I think I remember that verapamil acts by blocking the calcium channels.

    kind regards

    1. @Manuone: since you are using 2DG + Metformin, it would make sense to try to add cancer selective Calcium overload (IIRC your mother has GBM). Besides Trifluoperazine and Mibefradil mentioned above, there are others that may be useful, but unfortunately at high concentrations: Niguldipine, Fluoxetine and Resveratrol (probably Pterostilbene instead of it). I’m not sure if Doxycycline would help or antagonize the Calcium overload… Articles:
      Membrane-Depolarizing Channel Blockers Induce Selective Glioma Cell Death by Impairing Nutrient Transport and Unfolded Protein/Amino Acid Responses. PMID: 28087597
      The antidepressant fluoxetine induces necrosis by energy depletion and mitochondrial calcium overload. PMID: 27911858
      Resveratrol Specifically Kills Cancer Cells by a Devastating Increase in the Ca2+ Coupling Between the Greatly Tethered Endoplasmic Reticulum and Mitochondria. PMID: 27606689

      1. Thanks Ovidiu,
        Without a doubt it is a very important way to keep in mind.
        The main problem I see is that they are not accessible drugs.
        Mipsargin is only available for clinical use, it could be purchased from laboratories but it is very expensive and it would have to be formulated for iv.
        Bedaquiline is also for hospital use used for tuberculosis and very very expensive. Niguldipine and mibefradil exactly the same …..
        I only see accessible fluoxetine, trifluoperazine and resveratrol in high doses (maybe iv)

        kind regards

      1. Hi Jcancom,

        They did not accept the project. They said it was a process that would stop the production of their laboratory and would give very little benefit to the company. Two months of waiting for this response ……
        I’m still looking for other laboratories, I think it can be a powerful treatment too.

        Kind regards

        1. Manu, maybe we can discuss with them the option in which they could produce a supplement based on this Honokiol version? As it is one of my favourite natural extract, I will want to have it as a product in the supplement company I intend to start up in a few months. They may be motivated in this case to produce for you too. We will need to clarify what is the min volume we need to buy and what are the Europeans/US regulations regarding mito-based supplements.

          1. Daniel, it’s an excellent idea. I do not know if it will be a problem to be patented the formula. This can be solved with a minimum modification ….
            There are companies dedicated to personalize nutraceuticals. I hope response from several sites.

            1. D, this is fantastic news!

              I was so heartbroken when Manuone said that he couldn’t arrange the mito-HK synth. mito-HK is one of the strongest anti-cancer treatments that I have ever seen. I am so glad that Manuone picked up on this one and asked around about synthing it. I think continuing to ask around would be a great idea. A synth such as mito-HK could lead us onto the path of a great many others; there are many out there that do not appear technically demanding, but could offer high potential therapeutic activity.

              It has therapeutic activity even when dosed twenty fold lower than a no side effect treatment. Oftentimes it seems that we ignore these super fantastic treatments and then look at other treatments that are less safe and less effective. HK as you have noted elsewhere when dosed unformulated has been dosed up to the gram scale. So, we can be fairly comfortable with HK. The mito part needs to be considered more carefully, though there are already supplements such as mitoQ which are already sold online. It would help so many patients if there could be some sort of safe harbor understanding with supplements which reasonably could be designated as GRAS. We have discussed a fair number of these and it is not unreasonable to expect that they could have very powerful anti-cancer effects.

  19. Hi guys,

    Unfortunately my mother has gotten worse these days. She went from being well to a deep sedation in the same afternoon.
    I am using dexamethasone because I suspect it is due to brain inflammation.
    I hate corticosteroids and their adverse effects as well as their glucose elevation but I have no other option.
    I’ve thought about Avastin but getting it can be complicated. Another option is DMSO iv this is a potent anti-inflammatory.
    I could even bind some molecule to dmso to take advantage of its molecule-enhancing effect.
    I would appreciate any suggestions.
    Kind regards

    1. Hi Manuel,

      I am so sorry you have to deal with all these challenges. You did a great work so far and I am sure you will continue to do that.
      We used DMSO at 2ml in 100ml NaCl and latter 5ml DMSO. Clinics in Germany used even more but I preferred to stay in this range. Also sometimes combined with ultra low dose taxol https://www.cancertreatmentsresearch.com/ultra-low-dose-taxol/

      Before using it I sterilized DMSO with syringe filter of 0.2um. As it is a strong solvent is best to use filters with membrane suitable for strong solvents (I think some were made of Teflon – if you need more info please let me know and will check it for you).

      Kind regards,

    2. Hi Manuel,
      Any chance of getting an MRI done?
      Avastin hasn’t shown many benefits in GBM.

      I’d try anything that’s anti-inflammatory and has anti-cancer potential. Boswellia, Curcumin and Green Tea, in combination, come to mind. There’s synergy between those compounds.

      Here’s an interesting study, and with your knowledge, you might be able to pull this off:

      Take care

  20. Manuone, I greatly wish that I could help you. The best advice that I can think of is to try and find some way to mito-HK. China, someone with the needed lab skills, … . MitoHK and some of these other formulations look so amazingly powerful. The mouse
    dose that was used was twenty fold lower than a no side effect dose. This is very very powerful! If there were some way to connect up with this it could be of great help for your mother. Best wishes in a hard time, Jcancom

  21. Hi guys,

    Thank you all for your advice and kindness. These do not have a price for me.
    I have good news! It has recovered very well! She has recovered with a 2.5 mg dose of dexamethasone
    This confirms two things to me: that it is not a major tumor advance but an inflammation (at the moment controllable) in some part of the brain. If it were a large cerebral edema, it would not be controlled with that “small” amount of corticosteroids.
    I should try to reduce this dose and add greater amounts of anti-inflammatory drugs such as dmso iv, iv curcumin, green tea, boswellia in high doses and celebrex.
    I am striving to find a laboratory for mitohonokiol. I receive no response from anyone and I am somewhat disappointed.
    Now I’m going to take a deep breath and I’m going to make the therapy even better. I will share it shortly to receive your opinion. I never give up!
    Thanks all again. I am very happy to have found this blog and people like you.

    Kind regards

    1. That’s great news! I can understand your disappointment with your search for a laboratory, I’m going to try and find one here in Chile.

      1. Yes, this is great news! I was worried. Often with cancer, there can be progression and then one is no longer sure what can be done. Using this as a wakeup call to look around for sources for mito-HK etc. would be extremely wise. mito-HK simply looks too good not to go the extra mile for.

        It is so frustrating that cancer research takes so long to move ahead. The Brazilian wasp venom story has been out there for ten years and we still do not even have a mouse study published yet!

  22. Hi friends!

    I would like to hear your advice on the intravenous administration of DMSO to treat brain inflammation.

    Now I need to think about an important issue such as the supposed cerebral edema of my mother. She improves rapidly with corticosteroids in doses of 2 to 4 mg but I need to remove them as soon as possible.
    Daniel and other contacts suggested DMSO IV … the problem is that I can not find enough information about its intravenous use. I find some old study but they are restricted access. I have seen that it is not as innocuous as it is spoken and can cause side effects such as hemolysis, nausea, vomiting and elevations of liver values ​​…..
    It is true that a dose of 2ml of dmso dissolved in saline solution of 100ml is a very low concentration.
    I would appreciate it if you shared with me information about dmso iv especially dose and number of bolus in a week.
    I do not know if it would be compatible with the other therapies, you know that I handle a very wide cocktail.
    I will appreciate all the suggestions

    kind regards

    1. Sometime ago I was informed by a clinic using 2DG metronomic in combo with Insulin Potentiating Therapy, that after treating a patient for a longer period of time with 2DG, the clinic has to use less and less insulin to obtain the drop in blood glucose level. In other words, the patient was becoming more and more sensitive to insulin. This would indeed help Diabetic patients.

      The above anecdotal report from the clinic, firs well with previous observations of researchers:
      “During the three months period of 2-DG administration prior to tumor implantation, we observed a marginal decrease in the blood glucose level with a significant reduction in serum insulin concentration indicating increased insulin sensitivity”. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0132089

      Therefore, the clinic found in humans exactly what the researchers found in lab, i.e. 2DG administered for a longer period of time leads to an increased insulin sensitivity.

      I hope this answers your question.

      Kind regards,

  23. Thanks for your time and respond. I think I explained myself bad. Wanted to ask if people with diabetes mellitus could work this therapy for them??
    For the other hand, I was reading the 2DG procedure is not available on all hospitals. Iam from Spain. Do you know if there are some hospital able to apply metronomic 2DG?
    Like always, thanks a lot for your patience

    1. This is an intravenous therapy used at this point experimentally in advanced cancers. There is a clinical trial starting up on 2DG as anti viral but nothing for diabetes yet. Regarding clinics in Spain, you can ask Marcos or Manuel more info as they are located in Spain. Or you can address your questions on this Spanish website http://cancerintegral.com. It’s a very good website on cancer treatments run by a very clever man, Alfonso Fernánde. The website has a strong community that may be able to answer your questions related to treatment options in Spain.

      Kind regards,

  24. Hello Daniel

    Thank you for helping with the life saving information to many people like us .

    My brother has Papillary thyroid carcinoma with BRAF V600E Mutation . I am trying to find out the right combination of Offlabel drugs & supplements for this type of Mutation related Thyroid cancer that made me land here in your amazing website.

    Could you please suggest what are the Offlabel drugs to be used for BRAF V600E mutation Thyroid cancer. Which can block all pathways please …


    1. ravi, with BRAF mutation perhaps think metabolically.


      “Interestingly, the V600E BRAF mutation was recently shown to drive the Warburg effect.19 In fact, previous studies in both melanoma and thyroid cancer have shown that this mutation increases the expression of hypoxia-inducible factor-1α (HIF-1α),20,21 the major driver of the Warburg effect in cancer cells.22 Additionally, although mainly studied in the context of tumors different than melanoma, mutations in RAS family members, specifically KRAS, were shown to be associated with a glycolytic phenotype, with increased glucose uptake and lactate production. … ”

      Best Wishes, J

    2. Hello Daniel

      I hope you are doing well and safe.
      My brother has been battling BRAF + Pappillary thyroif cancer since 3 years. And we are using the below offlabel drugs :

      Curcumin (supplement)

      I would like to seek your guidance & help for the below questions.

      1.Are the offlabel drugs we are using for BRAF + tumor cells (PTC) are sufficient or are we missing blocking any other pathways or are we missing any other offlabel drugs to be used along with above? If so please suggest the offlabel drug names we need to include .

      2. Also i have come across an article which says IV C kills BRAF + cancer cells. My query is to make IV C more effective what all offlabel drugs to be taken before the IV C session to make it more effective. Kindly suggest the offlabel drug names.

      Thank you and have a nice day
      Looking forward to hear from you.


  25. Hi Teja,
    Welcome to the site! Like you, I have found the information here extremely valuable. I am sorry to hear about your brother, there is a lot of hope and solutions here! In order to help people better respond to your post, do you know the treatments he has undergone or is currently taking? Do you know the stage of the cancer and, if it has spread, to where?

    1. Hello Shanti

      Sorry i have missed your msg. My brother underwent surgery, RAI of 100mci but still there are cancer cells left behind and we are fighting with it correctly.

      We have been using Holy Basil & Tinospora cordifolia since couple of months due to their anti cancer properties, cancer hasn’t spread any where but lymph node invasion is observed that’s one of the reason we are concerned.

      We are currently using these offlabel drugs : Metformin, Desloratadine and Curcumin.

      Please let me know if any other offlabel drugs I should add to block any other pathways for BRAF mutated cancer.


  26. Hi all,

    What would be the best way to mimic metronomic 2dg in oral administration?

    Also, how does once access 3BP? We are based in Korea, and wouldn’t be able to travel overseas… unfortunately.


    1. Hi Manuone,

      Hope your mother is doing fine.
      My mom is fighting advanced stage ovarian cancer and all her earlier treatments didnt help her.
      We started her with offlabel drugs with medium dose chemotherapy.
      Im also giving oral 2 DG + Metformin + hydroxychloroquine.

      In recent ultrasound scan, radiologist says that, all the tumors has grown in size (largest being 16 cm)and every tumor has cystic formation inside by cells dying but as these tumors are bulging, compressing the adjacent organs causing complications . Please guide.

      skype : karthikreddie

      1. Hi Karthik,

        I feel your mother’s illness. It is hard and sad to go through these challenges but never lose hope.
        Unfortunately I can not advise you on much more than all the information shared in this magnificent blog.
        You should apply IV metronomic 2 DG instead of oral. You can try to convince the oncologist to contact the Lampidis Foundation and they can advise you.
        There are multiple combination options to treat cancer metabolically. Use the web search engine to browse the different articles published by Daniel. It will be very interesting that you can organize with the publication of “summary of this website”.
        Try to add drugs little by little and verify the interactions.
        The reported case of a friend and member of the blog can inspire you: https://www.cancertreatmentsresearch.com/good-news-from-marcos/

        Kind regards

        1. Hi Manuone,

          Thanks for your response.
          I had contacted Lampidis Foundation , requesting support on 2DG, they had replied tagging Daniel to help us on this, awaiting response.

          I’m giving most of the metabolic drugs that block major pathways of advanced stage cancer.
          Immunotherapy had caused lots of inflammation and flared up the disease,there is swelling in abdomen and inguinal lymph node.So,After watching the recommendation of a doctor to give Ketorolac to reduce the inflammation , we gave two IV infusion of Ketorolac 30mg yesterday with 100ml NS each and after the ketorolac IV, my mom’s tummy, legs, thigh swollen and her urine output drastically reduced.Creatinine and Blood urea values are normal.
          Kindly suggest.


  27. Hello Shanti

    Sorry i have missed your msg. My brother underwent surgery, RAI of 100mci but still there are cancer cells left behind and we are fighting with it correctly.

    We have been using Holy Basil & Tinospora cordifolia since couple of months due to their anti cancer properties, cancer hasn’t spread any where but lymph node invasion is observed that’s one of the reason we are concerned.

    We are currently using these offlabel drugs : Metformin, Desloratadine and Curcumin.

    Please let me know if any other offlabel drugs I should add to block any other pathways for BRAF mutated cancer.


  28. My name is Patricia Gupta .My mother is suffering from breast cancer which has metastised to her femur bone (in right leg ) and her backbone . We have got 2 DG from Germany . We want to get the 2DG administered metronomicaly. But we were curious as we were told that the medicine should be kept at a temperature of 10 degree celsius so that it doesn’t get spoilt . But since the medicine will be at room temperature (which is 32 degree celsius in daytime right now) while it is being administered metronomicaly won’t it get spoilt ?

    1. Hi Patricia,

      In general, to my knowledge, 2DG is not that sensitive so when given in normal conditions (normal room temperature) the stability should be very good. However, if the temperature is much higher you need to check the literature and see what is the 2DG stability as a function of temperature. I am sure you will find literature on that.

      Kind regards,

      1. Hi ,
        Thank you for your reply. I needed your opinion on one more thing . My mother has experienced acidosis due to metformin which she took with her 2DG bolus infusion . Can you maybe advise on how to manage that ? Also she started hormone therapy around a month back . She didn’t experience any major side effects due to it (a little pain but not that major ) but after she took zoladex she experienced major side effects (severe pain and anxiety issues which have had a major impact on her emotional well being ) . Is it advisable to discontinue the administration of zoladex ?

  29. Hi Daniel,
    Quick question… for the metronomic dosage of 2DG… can one take small amount orally like very hour or so? how can one determine the max dosage of that without increasing insulin? any practical way? would a continuous glucose monitor help in any way?… what is the correct combo with metformin if 2dg is given AFTER chemo… we are looking to use 2DG with chemo to increase effectiveness similar to the IPT+chemo+2DG ovarian cancer patient…. only we wont have access to the the IPT
    Thank you!

    1. Dear Catsrule,

      The question is good. While I would prefer to find access to IV metronomic, I understand that may be challenging sometimes. In this case, If I would still want to mimic the metronomic delivery, I would probably put the daily dose (typically delivered in a metronomic way) into one bottle of water, mix it well, and spread that over the whole day as much as possible (i.e. take that bit by bit as frequently as possible). The typical metronomic dose is 500mg to 1g/day. Not much. I would start taking that immediately after chemo is finished. I would also start taking metformin the same day. And Mebnedazole (e.g. 200mg/day) would also make sense to start the day after.

      This is of course not a medical advice, and it is just what I would do.

      Kind regards,

  30. Hi, Daniel,
    My name is JONGHA and I live in Korea.
    My mother suffers from ovarian cancer and lung cancer.
    I’ve used a lot of anticancer drugs, but it’s not working and I’ve got multiple cancers in my lungs and abdomen now.

    A few days ago, lung biopsy is added in a situation where in Imaging tests may also no longer standard treatment, lung cancer in the various issues won’t be looking.

    I can’t treat both lung and ovarian cancer, so I’m thinking about metabolic therapy
    I am interested in treatment of 2dg, 3bp, and Salinomycin on this website.

    I live in Korea and KAT-101 clinical trials have started in Korea, but we don’t have that.

    I went to Williams’ homepage, but there is no explanation for 3bp and Salinomycin anymore.

    I know it’s a stupid question, but what options do we have?

    (Please understand that it is written through a translator.)

    1. Dear Nathan,

      I am so sorry to hear about the challenges related to your mom’s health.

      For 2DG, 3BP and Sainomycin you woudl need a healthcare practitioner to help with intravenous administration. Woudl you have access to such help?

      Kind regards,

      1. Thank you for your reply.

        In Korea, it is not easy to do it directly due to legal problems.
        I think I should probably go abroad, is there a good hospital Daniel knows?

        It would be nice if it was an Asian country, but other places don’t matter.
        I look for information for more than 10 hours every day, but it’s not easy.
        Please tell me if there is a good hospital.

        I will share all the progress of the treatment.

        1. Salinomycin + Sulforaphane

          Pembrolizumab, Bevacizumab, and Cyclophosphamide (ovarian cancer)
          Complete responses were observed in 7.5% of women, whereas partial responses occurred in 40% of women, and 47.5% had stable disease as a response to the treatment. In addition, the ORR was 47.5%, with 95% obtaining clinical benefit from the treatment and 25% experiencing a durable response. The median PFS throughout the trial was 10 months.

          1. Thank you for your answer
            We already used both Pembrolizumab and Bevacizumab, but it didn’t work.

            And she was recently diagnosed with lung cancer as well. I am really worried because my kidney level is not good either.

            Thank you again for your reply.

            1. https://genomediscovery.org/2017/08/natural-product-derived-therapy-for-gynecologic-cancers-a-therapeutic-mix-encompassing-berberine-ber-dihydroartemisinin-dha-and-curcumin-curinhibits-the-expression-of-hdac6-acetylates-t/
              “Berberine (BER), Dihydroartemisinin (DHA), and Curcumin (CUR) or their analogs, either alone or in combination with other known anticancer drugs” may be used to inhibit the progression of ARID1A-mutated ovarian cancers ”
              (46–70% of clear cell carcinomas and 30–46% of endometrioid carcinomas harbor ARID1A mutations.)



              Theobromine https://pubmed.ncbi.nlm.nih.gov/9468592/

              Magnolol https://pubmed.ncbi.nlm.nih.gov/21757288/ Honokiol and Magnolol https://www.phcogj.com/article/975

Leave a Reply